Table 2.

Comparison of SARMS and WAVE/Surveyor methods in detecting EGFR exon 19 (del E746_A750), L858R, and T790M mutations from gefitinib/erlotinib-treated NSCLC patients

EGFR mutationDel E746_A750L858RT790M
Plasma DNA alone
    Total positive patients1579
    SARMS-positive1278
    WAVE/Surveyor-positive1424
    Concordance11/152/73/9
Plasma DNA and whole genome amplified
    Total positive patients18819
    SARMS-positive14818
    WAVE/Surveyor-positive1637
    Concordance12/183/86/19
  • NOTE: The data are displayed on a per patient basis.